Ricki Carroll, MD, MBE
Dr. Carroll is a complex care and palliative care pediatrician who has been with Nemours since 2015. She initially served as a pediatric hospitalist and subsequently completed fellowship training in Pediatric Hospice and Palliative Medicine at Nemours before accepting her current position. Dr. Carroll received both her Doctorate in Medicine as well as a Masters in Bioethics from the Perelman School of Medicine at the University of Pennsylvania. Dr. Carroll completed her pediatric residency training at the Children’s Hospital of Philadelphia. She has a Bachelor of Arts degree in Mathematics from Emory University.
In her role within the Skeletal Dysplasia and Osteogenesis Imperfecta Program, Dr. Carroll provides a medical home and manages children with a wide array of skeletal dysplasias. She focused her clinical care on infants, children, and young adults with medical complexity, as well as helping with pain and symptom management needs within this patient population. Her appointment also includes a part-time role with the palliative care team, where she serves as a palliative care attending at various times throughout the year. In addition, she is a member and served as co-chair of the Nemours’ Ethics and Patients’ Rights Committee.
Financial relationships
-
Type of financial relationship:OtherIneligible company:BiomarinTopic:PI for achondroplasia trialDate added:09/20/2023Date updated:09/20/2024
-
Type of financial relationship:OtherIneligible company:AscendisTopic:PI for achondroplasia trialDate added:09/20/2023Date updated:09/20/2024
-
Type of financial relationship:OtherIneligible company:PfizerTopic:co-I for achondroplasia trialDate added:09/20/2023Date updated:09/20/2024Relationship end date:05/01/2023
-
Type of financial relationship:OtherIneligible company:QEDTopic:co-I for achondroplasia trialDate added:09/20/2023Date updated:09/20/2024Relationship end date:07/31/2023
-
Type of financial relationship:OtherIneligible company:MedlifeTopic:PI for RCDP natural history trialDate added:09/20/2023Date updated:09/20/2024
-
Type of financial relationship:OtherIneligible company:ActioTopic:Consultant, related to metatropic dysplasiaDate added:09/20/2023Date updated:09/20/2024
-
Type of financial relationship:OtherIneligible company:GuidepointTopic:Consultant, related to skeletal dysplasia interventionsDate added:09/20/2023Date updated:09/20/2024
-
Type of financial relationship:OtherIneligible company:UltragenyxTopic:PI for OI trialDate added:09/20/2023Date updated:09/20/2024